First Tracks Biotherapeutics (NASDAQ:TRAX) Now Covered by Analysts at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. assumed coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a research note issued to investors on Thursday. The firm set an “overweight” rating and a $31.00 price target on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 64.28% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Barclays began coverage on shares of First Tracks Biotherapeutics in a research note on Wednesday. They issued an “overweight” rating and a $40.00 price objective for the company. UBS Group began coverage on shares of First Tracks Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $38.67.

First Tracks Biotherapeutics Stock Up 11.0%

Shares of First Tracks Biotherapeutics stock opened at $18.87 on Thursday. First Tracks Biotherapeutics has a 1-year low of $14.79 and a 1-year high of $26.80.